- Report
- August 2024
Japan
From €3969EUR$4,500USD£3,487GBP
- Report
- August 2024
United States
From €3969EUR$4,500USD£3,487GBP
- Report
- August 2024
Germany
From €3969EUR$4,500USD£3,487GBP
- Report
- August 2024
Spain
From €3969EUR$4,500USD£3,487GBP
- Report
- August 2024
United Kingdom
From €3969EUR$4,500USD£3,487GBP
- Report
- August 2024
- 880 Pages
Spain
From €3087EUR$3,500USD£2,712GBP
- Report
- August 2024
- 887 Pages
Japan
From €3087EUR$3,500USD£2,712GBP
The Hospital Acquired Infection Diagnostics market is a subset of the Infectious Disease Testing market. It focuses on the diagnosis of infections acquired in a hospital setting, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff). Diagnostics for these infections are typically conducted using molecular testing, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS). These tests are used to detect the presence of the pathogen, as well as to identify the strain and its resistance to antibiotics.
The Hospital Acquired Infection Diagnostics market is driven by the increasing prevalence of hospital-acquired infections, as well as the need for rapid and accurate diagnosis. This is especially important in the case of antibiotic-resistant infections, as timely diagnosis and treatment can help reduce the spread of the infection.
Some companies in the Hospital Acquired Infection Diagnostics market include Cepheid, Hologic, Becton Dickinson, Roche, and Abbott. Show Less Read more